H.U. Group Holdings, Inc. (4544) Stock Price

H.U. Group Holdings operates multiple business segments and provides a wide range of services. The main business segments include testing and related services, clinical diagnostic reagents, and healthcare-related services.

In the testing and related services business (LTS), SRL Corporation handles specialized and general testing services for large hospitals and mid-sized regional hospitals. H.U. Wellness Corporation provides health screening outsourcing services and supports corporate health insurance associations in addressing their challenges.

In the clinical diagnostic reagents business (IVD), Fujirebio Holdings Corporation manufactures and sells clinical diagnostic reagents domestically and internationally. Through its "Lumipulse" business and CDMO operations, it supplies products to medical institutions and contract clinical testing companies.

In the healthcare-related services business (HS), Nippon Sterilizing Corporation provides medical device sterilization services and surgical support services. Carelex Corporation operates a medical equipment rental business, and StarQ Gaia Corporation provides home-based services centered on visiting nursing care.

Through these operations, H.U. Group Holdings leverages clinical testing as its core business, with each subsidiary working together in an integrated and complementary manner to meet diverse needs in the medical and healthcare sectors.

H.U. Group Holdings aims to contribute to the future of health and medicine by creating new value in the healthcare sector. The company operates beyond the medical field into the broader healthcare sector and has established a medium-term management plan called "H.U.2030" to achieve sustainable growth. This plan envisions solving social challenges through co-creation, innovation, and bold initiatives while maximizing the use of management resources.

H.U. Group Holdings' medium-term management plan "H.U.2030" covers the five-year period from 2026 to 2030 and integrates management strategy with sustainability priorities. The plan strengthens three business segments: LTS (laboratory testing and related services), IVD (clinical diagnostic reagents), and HS (healthcare-related services), with the goal of maximizing corporate value. Specifically, LTS aims to establish operations in preventive healthcare and wellness, while IVD focuses on developing proprietary reagents and expanding market reach.

The company will deepen its group-wide integration strategy to respond quickly to changing business conditions and accelerate growth. It will lead market formation through the introduction of new testing items and development of proprietary reagents, while providing comprehensive solutions leveraging its customer base. Additionally, the company will optimize capital allocation, strengthen shareholder returns, and improve capital efficiency. Through these efforts, H.U. Group Holdings seeks to achieve sustainable growth and transform into a highly profitable organization.